Remove Biosimilars Remove Diabetes Remove Drug Development Remove Pharmaceutical Companies
article thumbnail

Ranibizumab biosimilar by Generium for Wet (Neovascular / Exudative) Macular Degeneration: Likelihood of Approval

Pharmaceutical Technology

Ranibizumab biosimilar is under clinical development by Generium and currently in Phase III for Wet (Neovascular / Exudative) Macular Degeneration. GlobalData’s report assesses how Ranibizumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

article thumbnail

Keeping Up with Recent Diabetes Therapies (Diabetes Mellitus)

PharmaShots

Shots: With an incurable nature and hefty medication costs, diabetes mellitus remains a global health concern and the seventh leading cause of death across the world. Moreover, the ceaseless trials of pharmaceutical companies in the research of drugs for several disease conditions have transformed the course of therapeutics.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Is India capable of ensuring equitable access to biopharmaceuticals?

Express Pharma

According to the World Health Organisation (WHO), an estimated two billion people across the world do not have access to essential medicines for life threatening diseases like cancer, AIDS and even autoimmune diseases like Type 1 diabetes. The post Is India capable of ensuring equitable access to biopharmaceuticals?

article thumbnail

Excellence Awards 2022 – Winners Announced!

Pharmaceutical Technology

The company is a clinical-stage biopharmaceutical startup that uses its artificial intelligence (AI)-enabled platform to measure brain biomarkers, including electroencephalogram (EEG) activity and behavioural patterns, wearable data, genetics and other factors, to drive targeted drug development in mental health.

article thumbnail

Exclusive Coverage: Global PHT Expo & Summit 2023

PharmaShots

As a renowned chemist, Dr. Senanayake discussed the need to adopt green chemistry in the process of drug development for cost reduction, timely innovation, and generating less waste than the standard process. According to me the main issue faced during the pandemic was the supply chain of pharmaceuticals. Dr. Mangesh.